期刊
CLINICA CHIMICA ACTA
卷 430, 期 -, 页码 63-70出版社
ELSEVIER
DOI: 10.1016/j.cca.2013.12.026
关键词
EGFR; Lung cancer; Biomarker; Plasma
资金
- Research Special Fund for Public Welfare Industry of Health [200902002-1]
- Chinese National Major Project for New Drug Innovation [2008ZX09312, 2008ZX09101, 2012ZX09101103, 2012ZX09303012]
- Chinese National High Technology Research and Development Program of China (863 Program) [2006AA02Z4A3, 2011AA02A110]
- Beijing Municipal Science and Technology Commission Major Project for New Drug Innovation [Z121107005112005, Z121102009212055]
- Chinese Central Health Authority Special Fund [B2009B124]
- Major Research Program of Hospital
- Chinese Academy of Medical Sciences
- Hospital of Chinese Academy of Medical Sciences 82 Peking Union Medical College [LC2012A18]
- Key Special Program for Science and Technology of Zhejiang Province [2007C13003]
- Zhejiang Beta Pharma Inc.
Background: The use of biomarkers for selecting non-small cell lung cancer (NSCLC) Patients for treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is essential. The aim of this study was to explore whether biomarkers detected in plasma were predictive for response to EGFR-TKIs and survival time of NSCLC patients. Methods: Tumor tissues and paired blood were collected from 134 advanced NSCLC patients treated with EGFR-TKIs. EGFR mutations in both types of specimens, and expression of transforming growth factor-alpha and beta one (TGF-alpha and TGF-beta 1) were assessed in NSCLC patients. Concentrations of circulating free DNA were detected in plasma from both NSCLC patients and healthy subjects. The clinical significance of EGFR mutations, levels of cytokines, and circulating free DNA was assessed in advanced NSCLC patients. Results: EGFR mutations were detected in 68 tumor samples and 17 plasma samples of 134 NSCLC patients. The concentrations of circulating free DNA were higher in NSCLC patients than in healthy subjects. Patients with high TGF-beta 1 level showed shorter overall survival and worse response to EGFR-TKIs than patients with low TGF-beta 1 level. Conclusions: Plasma levels of TGF-beta 1 may be a marker for predicting response to EGFR-TKIs and survival time in NSCLC patients. (C) 2013 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据